Crossmark

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Crossref DOI link: https://doi.org/10.1186/s12885-023-11291-6

Published Online: 2023-09-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kuo, Sung-Hsin

Tseng, Ling-Ming

Chen, Shou-Tung

Sagara, Yasuaki

Chang, Yuan-Ching

Yeh, Hsien-Tang

Kuo, Yao-Lung

Hung, Chih-Chiang

Lu, Tzu-Pin

Lee, Yi-Hsuan

Toi, Masakazu

Huang, Chiun-Sheng
Funding

Funding for this research was provided by:

Ministry of Health and Welfare, Taiwan (MOHW112-TDU-B-211-144002, MOHW112-TDU-B-211-144002)

National Science and Technology Council, Taiwan (No. 110-2314-B-002-199-, and No. 111-2314-B-002-285, No. 110-2314-B-002-199-, and No. 111-2314-B-002-285)
License Information

Text and Data Mining valid from 2023-09-14

Version of Record valid from 2023-09-14
More Information

Article History

Received: 3 April 2023

Accepted: 11 August 2023

First Online: 14 September 2023

Declarations

:

: In this randomized trial, written informed consent from participants should be obtained upon enrollment, and all processes of this trial will be executed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. The steering committees of the TBCC and ARO will supervise this study’s advancement. The Regional Research Ethics Committee C of the Institutional Review Board of the National Taiwan University Hospital approved this prospective randomized trial (No. 201902048MINC), which has been registered at ClinicalTrials.gov (NCT04046159).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below